|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8520 EUR | -1.39% |
|
+0.24% | -37.54% |
| 06-18 | AB Science Secures US Patent for Prostate Cancer Therapy | MT |
| 06-18 | AB Science Secures New U.S. Patent for Masitinib |  |
Projected Income Statement: AB Science
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.97 | 1.072 | 1.174 | 1.2 | 1.3 | 1.6 |
| Change | - | - | 10.5% | 9.53% | 2.21% | 8.33% | 23.08% |
| EBITDA | - | -11.16 | -5.416 | - | - | - | - |
| Change | - | - | 51.46% | - | - | - | - |
| EBIT 1 | - | -13.43 | -6.083 | 0.639 | -6.5 | -6.4 | - |
| Change | - | - | 54.7% | 110.5% | -1,117.21% | 1.54% | - |
| Interest Paid 1 | - | - | - | -2.196 | -1 | -1 | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - |
| Net income | -13.62 | -10.05 | -7.831 | - | - | - | - |
| Change | - | 26.2% | 22.06% | - | - | - | - |
| Announcement Date | 01/03/23 | 15/05/24 | 13/05/25 | 13/05/26 | - | - | - |
1EUR in Million
Estimates
Forecast Balance Sheet: AB Science
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - |
| Announcement Date | 01/03/23 | 15/05/24 | 13/05/25 | 13/05/26 | - | - | - |
Estimates
Cash Flow Forecast: AB Science
| Fiscal Period: December | 2023 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| CAPEX 1 | 0.345 | - | - | - | - |
| Change | - | - | - | - | - |
| Free Cash Flow (FCF) 1 | -17.22 | -4.571 | -6.4 | -3.6 | -3.9 |
| Change | - | - | -40.01% | 43.75% | -8.33% |
| Announcement Date | 15/05/24 | 13/05/26 | - | - | - |
1EUR in Million
Estimates
Forecast Financial Ratios: AB Science
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|---|
Profitability | |||||||||
| EBITDA Margin (%) | - | - | - | -1,150.31% | -505.3% | - | - | - | - |
| EBIT Margin (%) | - | - | - | -1,384.43% | -567.53% | 54.43% | -541.67% | -492.31% | - |
| EBT Margin (%) | - | - | - | - | - | - | - | - | - |
| Net margin (%) | - | - | - | -1,035.88% | -730.61% | - | - | - | - |
| FCF margin (%) | - | - | - | -1,774.85% | - | -389.35% | -533.33% | -276.92% | -243.75% |
| FCF / Net Income (%) | - | - | - | 171.34% | - | - | - | - | - |
Profitability | |||||||||
| ROA | -38.87% | -33.87% | -44.16% | -34.02% | -15.62% | 1.67% | - | - | - |
| ROE | 64.88% | 67.67% | 46.26% | 42.29% | 34.99% | 7.6% | - | - | - |
Financial Health | |||||||||
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - | - |
| Debt / Free cash flow | - | - | - | - | - | - | - | - | - |
Capital Intensity | |||||||||
| CAPEX / Current Assets (%) | - | - | - | 35.57% | - | - | - | - | - |
| CAPEX / EBITDA (%) | - | - | - | -3.09% | - | - | - | - | - |
| CAPEX / FCF (%) | - | - | - | -2% | - | - | - | - | - |
Items per share | |||||||||
| Cash flow per share 1 | 0.3939 | 0.1871 | 0.1559 | 0.1044 | 0.125 | 0.1392 | - | - | - |
| Change | - | -52.49% | -16.7% | -33.05% | 19.79% | 11.34% | - | - | - |
| Dividend per Share 1 | - | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - | - |
| Book Value Per Share 1 | -0.3727 | -0.4978 | -0.7649 | -0.3615 | -0.3718 | -0.2352 | - | - | - |
| Change | - | -33.57% | -53.66% | 52.74% | -2.86% | 36.75% | - | - | - |
| EPS 1 | -0.3402 | -0.3044 | -0.29 | -0.2413 | -0.15 | -0.03 | - | - | - |
| Change | - | 10.53% | 4.71% | 16.79% | 37.84% | 80% | - | - | - |
| Nbr of stocks (in thousands) | 45,540 | 46,859 | 46,861 | 50,891 | 65,248 | 72,947 | - | - | - |
| Announcement Date | 30/04/21 | 01/03/22 | 01/03/23 | 17/05/24 | 27/05/25 | 21/05/26 | - | - | - |
1EUR
Estimates
| 2026 * | 2027 * | |
|---|---|---|
| P/E | - | - |
| PBR | - | - |
| EV / Sales | 55.7x | 51.5x |
| Yield | - | - |
EPS & Dividend
Y-o-Y evolution of P/E
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AB Stock
- A8D Stock
- Financials AB Science
Select your edition
All financial news and data tailored to specific country editions
